Roivant Sciences launched the new subsidiary Hemavant, which hit the ground running with a licensing agreement from Eisai for RVT-2001, a potential first-in-class small molecule SF3B1 modulator.

Takeda

With two assets licensed from Takeda, Oak Hill Bio launched with a focus on developing therapeutics for patients and extremely preterm infants who are suffering from rare autoimmune diseases.

BioSpace presented its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.

With $60 million in hand, Recludix Pharma launched with a mission to develop three SH2 domain inhibitor programs targeting STAT3, STAT6, and an undisclosed non-STAT target for cancer and inflammatory disease targets. 

With $19 million in seed funding led by the Retinal Degeneration Fund, Opus Genetics launched with a mission to develop gene therapies for rare forms of blindness driven by genetic mutations.

Shoreline Biosciences is developing an off-the-shelf, targeted, allogeneic approach to natural killer (NK) and macrophage cell therapies which the immunotherapy company’s chairman and CEO believes is one-of-a-kind.

A made-in-Canada life sciences company, Nimium Therapeutics, launched to develop novel therapies for patients with cardiometabolic diseases.

Biopharma company curator Flagship Pioneering, which has launched companies such as Moderna, announced a massive infusion of cash that will be used to support the development and launch of new companies taking aim at a myriad of diseases and global health threats.

Venture capitalist Chamath Palihapitiya is raising $800 million to finance four more special purpose acquisition companies (SPAC) that will be focused on taking biotech companies public.

Organon on June 3 celebrated the launch of the global women’s health company with employees and women from around the world, as the Organon executive leadership team rang the opening bell at the New York Stock Exchange (NYSE). Recognizing the need to listen to and act on women’s experiences to address the challenges in women’s health, Organon gathered voices from around the world to create the “Wall of Voices,” a multimedia installation outside of the NYSE.